Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer

International Journal of Clinical Oncology

Volumn 7, Issue 2, 2002, Pages 114-119

  Kim, Y H ^a   Kim, J S ^a   Choi, Y H ^a   In, K H ^a   Park, H S ^b   Hong, D S ^b   Jeong, T J ^c   Lee, Y Y ^c   Nam, E ^d   Lee, S N ^d   Lee, K S ^e   Kim, H K ^e  

^a Korea University College of Medicine   (South Korea)

^b Soonchunhyang University   (South Korea)

^c Hanyang University   (South Korea)

^d Ewha Womans University School of Medicine   (South Korea)

^e The Catholic University of Korea   (South Korea)

Author keywords

Chemotherapy naive patients; Cisplatin; Docetaxel; Non small cell lung cancer

Indexed keywords

CISPLATIN; DOCETAXEL; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PACLITAXEL; TAXOID;

ADULT; AGED; ALOPECIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; INFECTION; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; SKIN MANIFESTATION; TREATMENT OUTCOME; VOMITING; CHEMICALLY INDUCED DISORDER; HEMATOLOGIC DISEASE; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 0036001439     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101470200015     Document Type: Article

References (20)

1. Annual report of the central registry in Korea - 1998 (based on registered data from 124 hospitals)
2. Non-small-cell lung cancer
3. Treatment of metastatic non-small-cell lung cancer
4. Chemotherapy of lung cancer
5. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
6. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: A meta-analysis of response, toxicity, and survival
7. Paclitaxel
8. Comparative in vitro cytotoxicity of Taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines
9. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer
10. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer
11. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer
12. An update on European randomized studies in non-small-cell lung cancer
13. An update on North American randomized studies in non-small-cell lung cancer
14. Overview of docetaxel (Taxotere)/cisplatin in non-small-cell lung cancer
15. Docetaxel and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC): A multicenter phase II trial
16. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial
17. Preliminary results of a multi-centre Asian trial of docetaxel and cisplatin in advanced non-small cell lung cancer
18. Lung cancer highlight
19. Survival determinants in extensive-stage non-small-cell lung cancer: The southwest Oncology Group experience
20. Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small-cell lung cancer (NSCLC): A multicenter phase III study